1 **Category:** Original Article

- 2 Running head: GWAS on 'neck or shoulder pain'
- 3

4 A genome-wide association study finds genetic variants

5 associated with neck or shoulder pain in UK Biobank

- 6 **Authors:** Weihua Meng^{1*}, Brian W Chan^{1*}, Cameron Harris¹, Maxim B Freidin²,
- 7 Harry L Hebert¹, Mark J Adams³, Archie Campbell⁴, Caroline Hayward⁵, Hua Zheng⁶,

8 Xianwei Zhang⁶, Lesley A Colvin¹, Tim G Hales⁷, Colin NA Palmer¹, Frances MK

9 Williams², Andrew McIntosh³, Blair H Smith¹.

10

- ¹ Division of Population Health and Genomics, Medical Research Institute, Ninewells
- 12 Hospital and School of Medicine, University of Dundee, Dundee, UK, DD2 4BF
- 13 ² Department of Twin Research and Genetic Epidemiology, School of Life Course

14 Sciences, King's College London, London, UK, SE1 7EH

- ³ Division of Psychiatry, Edinburgh Medical School, University of Edinburgh,
 Edinburgh, UK, EH10 5HF
- ⁴ Centre for Genomic and Experimental Medicine, Institute of Genetics and
 Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh,
 UK, EH4 2XU
- ⁵ Medical Research Council Human Genetics Unit, Institute of Genetics and
 Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh,
 UK, EH4 2XU
- ⁶ Department of Anaesthesiology, Tongji Hospital, Tongji Medical College, Huazhong
- 24 University of Science and Technology, Wuhan, China
- ⁷ Institute for Academic Anaesthesia, Division of Systems Medicine, School of

26 Medicine, Ninewells Hospital, University of Dundee, Dundee, UK

²⁷ * These two authors contributed to this paper equally.

28 **Corresponding Author:** Dr Weihua Meng, Ph.D.

29 Address: Division of Population Health and Genomics, School of Medicine,

30 University of Dundee, Dundee, UK, DD2 4BF.

31 Tel: +44 1382383419; Fax: +44 1382383802. E-mail: <u>w.meng@dundee.ac.uk</u>

32

Funding Sources: This study was mainly funded by the Wellcome Trust Strategic Award "Stratifying Resilience and Depression Longitudinally" (STRADL) with reference number 104036/Z/14/Z and by the GCRF academic exchange visits to China funded by the University of Dundee.

37 Generation Scotland: Scottish Family Health Studies (GS:SFHS) received core 38 support from the Chief Scientist Office of the Scottish Government Health 39 Directorates (CZD/16/6) and the Scottish Funding Council (HR03006).

TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.

45 **Conflicts of Interest:** None declared.

46

Significance: This is the first genome-wide association study on neck or shoulder pain. We have identified 3 genetic loci (an intergenic region in chromosome 17, the *FOXP2* gene in chromosome 7, and the *LINC01572* gene in chromosome 16) that are associated with neck or shoulder pain using the UK Biobank cohort, among

which the *FOXP2* gene and the *LINC01572* gene were weakly replicated by the Generation Scotland: Scottish Family Health Study (P < 0.05). The SNP heritability was 0.11, indicating neck or shoulder pain is a heritable trait. The tissue expression analysis suggested that neck or shoulder pain was related to multiple brain tissues, indicating the involvement of neuron function. The results will inform further research in the characterisation of the mechanisms of neck or shoulder pain.

57

58 ABSTRACT

59 **Background:** Common types of musculoskeletal conditions include pain in the neck 60 and shoulder areas. This study seeks to identify the genetic variants associated with 61 neck or shoulder pain based on a genome-wide association approach using 203,309 62 subjects from the UK Biobank cohort and look for replication evidence from the 63 Generation Scotland: Scottish Family Health Study (GS:SFHS) and TwinsUK.

Methods: Cases in the UK Biobank were determined by a question which asked the participants if they had experienced pain in the neck or shoulder in the previous month influencing daily activities. Controls were the UK Biobank participants who reported no pain anywhere in the last month. A genome-wide association study was performed adjusting for age, sex, BMI and 9 population principal components. Significant and independent genetic variants were then sent to GS:SFHS and TwinsUK for replication.

Results: We identified 3 genetic loci that were associated with neck or shoulder pain in the UK Biobank samples. The most significant locus was in an intergenic region in chromosome 17, rs12453010, having $P = 1.66 \times 10^{-11}$. The second most significant locus was located in the *FOXP2* gene in chromosome 7 with $P = 2.38 \times 10^{-10}$ for rs34291892. The third locus was located in the *LINC01572* gene in chromosome 16

with $P = 4.50 \times 10^{-8}$ for rs62053992. In the replication stage, among 4 significant and independent genetic variants, rs2049604 in the *FOXP2* gene and rs62053992 in the *LINC01572* gene were weakly replicated in GS:SFHS (P = 0.0240 and P = 0.0202, respectively). None of the single nucleotide polymorphisms (SNPs) were replicated in the TwinsUK cohort (P > 0.05).

Conclusions: We have identified 3 loci associated with neck or shoulder pain in the
UK Biobank cohort, two of which were weakly supported in a replication cohort.
Further evidence is needed to confirm their roles in neck or shoulder pain.
Key words: neck pain, shoulder pain, GWAS, genetics, FOXP2, UK Biobank

85

86 **INTRODUCTION**

87 Musculoskeletal pain in the neck and shoulder areas is a major health problem for adults of working age as well as for elderly populations (1). Neck and shoulder pain 88 are prevalent forms of self-reported musculoskeletal pain (2). The aetiologies of neck 89 90 and shoulder pain may be complicated since both regional lesions and systemic disorders outside the cervicobrachial area may cause pain at that location (3,4). In 91 addition, lesions in the neck can lead to pain in the shoulder and vice versa (5). 92 Many people also have difficulty in describing and differentiating pain in these areas 93 accurately. For these reasons, neck or shoulder pain is often discussed as a single 94 95 entity (6).

96 Epidemiological studies have suggested that the prevalence of neck pain is 6-22% 97 and 7-27% for shoulder pain (7–9). The Global Burden of Disease Study 2010 found 98 that of the 291 conditions studied, neck or shoulder pain as a single entity ranked 99 21st in overall burden on society, and 4th in terms of overall disability (8). The 100 updated Global Burden of Disease Study 2016 also indicated that neck pain was a

101 top five cause of years lived with disability (YLD) in high-income, and high-middleincome countries.(10) Risk factors associated with neck or shoulder pain conform to 102 the biopsychosocial model; specifically, they include older age, being female, high 103 104 body mass index (BMI), previous injury, strenuous occupation and diabetes mellitus (3,11–14). Although mechanical exposure is associated with increased risk of pain in 105 the neck and shoulder, this explains only part of these complaints (15). Because of 106 107 the biopsychosocial factors involved, treating neck or shoulder pain successfully is a challenge. In a study of neck, shoulder and arm pain, only 25% of the patients made 108 109 a complete recovery after 6 months (16). Estimated rates of remission 1 year after 110 neck or shoulder pain onset were between 33-55% (17-20).

Genetic studies have identified genes associated with neck or shoulder pain. Twin studies have shown that there is a genetic role in neck pain (14), though in keeping with many traits the genetic component becomes smaller with age (21,22). Nonetheless, in adolescents as much as 68% of variance in neck pain liability could be attributed to genetic factors (23). So far there has been no genome-wide association study (GWAS) published on neck or shoulder pain.

This study seeks to identify the genetic variants associated with neck or shoulder pain based on a GWAS approach in a cohort of 203,309 subjects from the UK Biobank cohort and to test significant results for replication in the Generation Scotland: Scottish Family Health Study (GS:SFHS) and TwinsUK. Similar approaches have been used to examine back pain, knee pain, and headaches in the UK Biobank cohort (24–26).

124 METHODS

125 Participants and the genetic information of cohorts

Discovery cohort - The UK Biobank (https://www.ukbiobank.ac.uk/) is a project 126 facilitating research into health and disease and involves over 500,000 participants 127 aged between 40-69 years old at recruitment. Participants completed a detailed 128 questionnaire which examined lifestyle, demographic factors, and clinical history. 129 130 Participants also underwent clinical measures and baseline body measurements such as height and weight. Biological samples including urine, saliva, and blood 131 132 were also provided. The National Research Ethics Service granted ethical approval to the UK Biobank (reference 11/NW/0382). The genetic information of 500,000 133 participants was released to approved researchers in March 2018. The 134 135 corresponding author of this paper was granted access to the genetic information under UK Biobank application number 4844. Detailed guality control information 136 pertaining to these genotypes was described by Bycroft et al (27). 137

Replication cohort 1 - Generation Scotland: Scottish Family Health Study (GS:SFHS) 138 is a multi-institutional, family-based cohort involving over 20,000 volunteer 139 participants aged between 18-98 years old at recruitment, who provided blood 140 samples from which DNA was extracted. Similarly, participants also completed 141 questionnaires to provide detailed phenotypic and sociodemographic information. 142 143 Clinical and biochemical measurements were also collected for the purpose of research. Permission was obtained for linkage of research data to routine health 144 data in the form of electronic health records (28,29). Ethical approval for GS:SFHS 145 was obtained from the Tayside Committee on Medical Research Ethics (on behalf of 146 the National Health Service) with reference Number 05/S1401/89. The genetic 147 information relating 20,000 participants was released to the corresponding author of 148

this paper in March 2018 for pain-related research. Detailed quality controlinformation pertaining to these genotypes was described by Hall et al (30).

Replication cohort 2 - The TwinsUK cohort is a UK nationwide registry of volunteer 151 152 same sex twins. It has recruited 14,274 registered twins aged between 16 and 98 years. Collection of data and biological materials commenced in 1992 and is ongoing. 153 During study participation, participants regularly complete health and lifestyle 154 155 questionnaires and visit collaborating clinics and hospitals for clinical evaluation. Ethical approval was provided by the Research Ethics Committee at Guy's and St. 156 157 Thomas' NHS Foundation Trust. TwinsUK has the genetic information relating to 158 6,921 participants. Detailed quality control information pertaining to the genetic information was described by Moayyeri et al (31). 159

160 Phenotypic definitions on neck or shoulder pain

Discovery cohort - UK Biobank: Participants were offered a pain-related questionnaire, which included the question: 'in the last month have you experienced any of the following that interfered with your usual activities?'. The options were: 1. Headache; 2. Facial pain; 3. Neck or shoulder pain; 4. Back pain; 5. Stomach or abdominal pain; 6. Hip pain; 7. Knee pain; 8. Pain all over the body; 9. None of the above; 10. Prefer not to say. Participants could select more than one option. (UK Biobank Questionnaire field ID: 6159).

In this study, cases were defined as participants who reported having activity limiting pain in the neck or shoulder in the past month (option 3), regardless of whether they reported pain in other regions. The controls were defined as participants who chose the 'None of the above' option.

172 Replication cohort 1 – GS:SFHS: Participants were first asked "Are you currently
173 troubled by pain or discomfort, either all the time or on and off?". If yes was selected,

then the participants were asked "Have you had this pain or discomfort for more than 3 months?". If yes was selected once again, then they were asked "Where is this pain or discomfort?" with options of 'Back pain', 'Neck or shoulder pain', 'Headache, facial or dental pain', 'Stomach ache or abdominal pain', 'Pain in your arms, hands, hips, legs or feet', 'Chest pain', and 'Other pain'. If a participant selected the 'Neck or shoulder pain', then he/she was defined as a case. All other subjects were defined as controls.

181 Replication cohort 2: TwinsUK: participants were asked 'In the past three months, 182 have you had pain in your neck or shoulders?' Those who answered 'Yes' were 183 defined as cases. Those who answered 'No' were defined as controls. Those with 184 missing answers were not included in the study.

185 Statistical Analysis

Discovery cohort – UK Biobank: BGENIE (<u>https://jmarchini.org/bgenie/</u>) was used as the main GWAS software. Single nucleotide polymorphisms (SNPs) with imputation INFO scores < 0.1, minor allele frequency (MAF) < 0.5% were removed, as well as SNPs that failed Hardy-Weinberg tests $P < 1.0 \times 10^{-6}$.

BGENIE was used to perform association studies using linear association tests, 190 adjusting for age, sex, BMI, 9 population principle components, genotyping arrays, 191 and assessment centres. Chi-square testing was used to compare gender difference 192 193 between cases and controls. T-tests were used to compare age and BMI between 194 case and control groups using IBM SPSS 22 (IBM Corporation, New York). As is standard in GWAS, SNP associations were considered significant when $P < 5.0 \times 10^{-1}$ 195 196 ⁸. Genome-wide Complex Trait Analysis (GCTA) software was used to calculate SNP-based or narrow-sense heritability (32). Significant and independent SNPs from 197 the GWAS results of the discovery cohort were then sent to replication cohorts for 198

replication. These significant and independent SNPs were defined by FUMA with r^2 (linkage disequilibrium score) < 0.6 with any other significant SNPs.

Replication cohort 1 – GS:SFHS: GCTA fastGWA1.92.4 was the main software used for replication. (https://cnsgenomics.com/software/gcta/#fastGWA). SNPs with INFO scores < 0.3, or MAF < 1% were removed, as well as SNPs that failed Hardy-Weinberg tests $P < 1.0 \times 10^{-6}$. FastGWA was used to perform association studies using a mixed-effects linear model adjusting for age, sex, BMI, and 9 population principle components. Relatedness was adjusted for via a genetic kinship matrix.

207 Replication cohort 2 – TwinsUK: GEMMA v 0.98.1 was used for replication 208 (<u>https://github.com/genetics-statistics/GEMMA</u>). A mixed-effects linear model 209 adjusting for age, sex, BMI, and relatedness via a genetic kinship matrix was used.

210 Meta-analysis of the significant and independent SNPs combining the UK Biobank, 211 GS:SFHS and TwinsUK was performed using GWAMA 2.2.2 212 (https://genomics.ut.ee/en/tools/gwama).

Post-GWAS analysis: This study used FUMA as a main annotation tool for viewing
and annotating GWAS results (33). It applied SNP functional annotations and
generated a corresponding GWAS Manhattan plot.

MAGMA v1.06 (integrated in FUMA) was used to perform gene-based association 216 analysis and gene-set analysis, both of which were generated from GWAS summary 217 218 statistics (34). For gene-based association analysis, all SNPs located in protein 219 coding genes are mapped to one of 19,123 protein coding genes. The default SNPwise model (mean) was applied. We tested the joint association of all SNPs in the 220 221 gene with the phenotype by aggregating the SNP summary statistics to the level of whole genes. In gene-set analysis, individual genes were aggregated to groups of 222 genes sharing certain biological, functional or other characteristics. This aims to 223

224 elucidate the involvement of specific biological pathways or cellular functions in the phenotype. GTEx 225 aenetic aetiology of а (also integrated in FUMA. 226 https://www.gtexportal.org/home/) provided the results of tissue expression analysis. Genetic correlation analysis was also performed to identify genetic correlation 227 between neck or shoulder pain and 234 complex traits based on the online tool LD 228 hub v1.9.0 (http://ldsc.broadinstitute.org/ldhub/). Any P value less than 2.1 x 10⁻⁴ 229 230 (0.05/234) was considered statistically significant by Bonferroni adjusted testing.

231

232 **RESULTS**

233 GWAS Results

234 In the UK Biobank, 775,252 responses to all options were received for the specific 235 pain question. Of the 501,708 participants in the study, 123,061 participants reported 236 having experienced activity limiting pain in the neck or shoulder in the previous month. 213,408 participants chose the 'None of the above' option which meant they 237 238 did not have activity limiting pain anywhere in the previous month. To create a homogeneous dataset, we first removed samples according to their ancestry 239 240 information. In addition, those who were related to one or more others in the cohort 241 (a cut-off value of 0.044 in the generation of the genetic relationship matrix) and those who failed quality control were also removed. The final number of those 242 243 included in the case group after the above exclusions was 53,994 (28,093 males, 244 25,901 females). 149,312 (71,480 males, 77,832 females) individuals were included in the control group. After SNP guality control, there were 9,304,965 SNPs available 245 246 for GWAS analysis. Clinical characteristics of the case and control groups were compiled (Table 1). Age, sex, and BMI were all found to be significantly different (P < 247 0.001) between cases and controls. Three genetic loci including 4 significant and 248

249 independent SNPs reached a GWAS significance of $P < 5 \times 10^{-8}$ (Figure 1, Table 2). The most significant locus was located in an intergenic region in chromosome 17. 250 The SNP from this location of highest significance was rs12453010 ($P = 1.66 \times 10^{-10}$). 251 252 The second locus was found in the FOXP2 gene located in chromosome 7, and the most significant SNP from this locus was rs34291892 ($P = 2.38 \times 10^{-10}$). The third 253 locus was the LINC01572 gene located in chromosome 16, and the most significant 254 SNP in this locus was rs62053992 ($P = 4.50 \times 10^{-10}$). The SNP heritability (liability 255 scale) from GCTA was 0.11+0.017. 256

257 These 4 significant and independent SNPs were tested for replication in GS:SFHS 258 and TwinsUK. Among 20,032 subjects in the GS:SFHS subjects, 19,632 had complete relevant information. The whole-genome fastGWA results did not find any 259 260 SNPs with GWAS significance associated with neck or shoulder pain. (Supplementary Figure S1). Among the 4 SNPs from the discovery cohort, 261 rs2049604 in the FOXP2 gene and rs62053992 in the LINC01572 gene were 262 263 replicated weakly (P = 0.0240 and 0.0202, respectively) (Table 2). Of the 6,921 individuals in TwinsUK with genetic information, 3,982 of them had valid relevant 264 information on phenotypes and covariates. None of the 4 SNPs were replicated in 265 the TwinsUK cohort (P > 0.05). 266

Meta-analysis of the 4 significant and independent hits, combining UK Biobank, GS:SFHS and Twins UK found that the significance of their associations was increased (Table 2).

270 FUMA Analysis

In gene-based association analysis by MAGMA, 26 genes were found to be associated with neck or shoulder pain, all of which are represented in Supplementary Table S1. The most significant gene was *FOXP2* ($P = 1.62 \times 10^{-11}$), which is located

in chromosome 7.

In gene-set analysis conducted by MAGMA, 10,651 gene-sets were analysed using the default competitive test model. None of these gene-sets met genome-wide significance ($P < 4.7 \times 10^{-6}$ (0.05/10651)).

Tissue expression analysis was conducted by GTEx, and the relationship between 278 279 tissue specific gene expression and genetic associations was tested by using the 280 average gene expression in each tissue type as a covariate. Two analyses were carried out, one investigating 30 general tissue types (Figure 2) and the other looking 281 282 at 53 specific tissue types (Figure 3). Tissue expression analysis in 30 tissue types found expression in brain tissue to be the most significant ($P = 9.53 \times 10^{-5}$). Only 283 expression in brain and pituitary tissue reached significant values of $P < 1.67 \times 10^{-3}$ 284 285 (0.05/30). Tissue expression analysis of 53 specific tissue types by GTEx found expression in the nucleus accumbens of the basal ganglia to be the most significant 286 $(P = 3.55 \times 10^{-5})$. In addition, the top 6 significant associations were all from brain 287 288 tissues.

The genetic correlation analysis using the LD hub (v1.9.0) showed that symptoms of 289 depression had the largest significant and positive genetic correlation with neck or 290 shoulder pain (rg = 0.5522, $P = 3.41 \times 10^{-30}$), followed by insomnia (rg = 0.5377, P =291 292 1.21 x 10⁻²¹). It was also found that the age at which they have their first child had 293 the most significant and negative genetic correlations with neck or shoulder pain (rg = -0.4812, $P = 8.95 \times 10^{-37}$), followed by college completion (rg = -0.4706, $P = 7.26 \times 10^{-37}$) 294 10⁻²⁶). All the phenotypes with significant genetic correlation with neck or shoulder 295 296 pain are shown in Table 3.

297

298 **DISCUSSION**

We have performed a GWAS on neck or shoulder pain using the UK Biobank resource and found 3 loci that have reached genome-wide significance ($P < 0.05 \times 10^{-8}$). They are the *FOXP2* gene in chromosome 7, the *LINC01582* gene in chromosome 16 and an intergenic area in chromosome 17. In the replication stage, the *FOXP2* and *LINC01582* loci were weakly supported by the GS:SFHS cohort, but not by TwinsUK.

305 FOXP2 belongs to the forkhead-box transcription factor family and encodes a 715 amino acid long transcription factor (35). It may have 300-400 transcription targets, 306 307 and has a forkhead/winged helix binding domain with 2 polyglutamine tracts adjacent 308 to each other due to a mixture of CAG and CAA repeats (36,37). FOXP2 is a gene shown to be vital in the neural mechanisms underpinning the development of speech 309 310 and language. A previous study described a family with developmental verbal dyspraxia, where affected individuals had a loss of function mutation in the FOXP2 311 gene (38). Affected individuals in the family had difficulty with the selection and 312 313 sequencing of fine orofacial muscular movements needed to articulate words, as well as deficits in language and grammatical skills. FOXP2 also plays a role in regulating 314 'hub' genes Dlx5 and Svt4 in animal models, which are important for brain 315 316 development and function (39-41). The mutations in the FOXP2 gene were also associated with decreased grey matter in the cerebellum (42). 317

Notably, *FOXP2* is expressed in several regions of the brain, namely the basal ganglia, locus coeruleus, parabrachial nucleus, and thalamus. All of these regions have been previously implicated in the modulation of pain (43–46), and also concur with the tissue expression analysis (Figure 2, Figure 3) which suggests that the central nervous system modulates neck or shoulder pain. A recent GWAS study suggested that *FOXP2* is a candidate gene for multisite chronic pain (47). Further

studies into the location and function of the transcription targets of *FOXP2* wouldalso provide valuable insight.

326 The LINC01572 gene in chromosome 16 was also replicated in this study, with 327 rs62053992 having the *P* value at 4.5×10^{-8} in the discovery cohort and at 0.02 in the GS:SFHS. The gene is 384kb long, and was recently suggested to be related with 328 polycystic ovary syndrome (48). However, studies of this gene have been very 329 330 limited. Further replication evidence should be sought to confirm its role in neck or 331 shoulder pain. Although the locus in chromosome 17 was not replicated, it was the 332 most significantly associated in the discovery cohort with rs12453010 having the lowest P value of 1.66 x 10^{-11} . Analysis of this locus is also difficult as it is a gene 333 334 desert area. The nearest neighbouring gene is CA10, which encodes a protein belonging to the carbonic anhydrase family and is responsible for catalysing the 335 336 hydration of carbon dioxide. It is also thought to contribute to central nervous system 337 development particularly in the brain (49).

The results of the meta-analysis of the 4 significant and independent SNPs combining 3 cohorts suggested that the loci identified by the UK Biobank cohort were supported by the GS:SFHS and TwinsUK. It is likely that the sample size in the TwinsUK (N= 3,982) was too small to replicate the loci for such a heterogeneous phenotype as neck or shoulder pain. In particular, for the 4 SNPs chosen for replication, the power to achieve a *P* value < 0.05 in the given TwinsUK sample ranged between 11.6% to 15.8% (50).

The SNP heritability of neck or shoulder pain was 0.11. This is similar to that of back pain (0.11), greater than knee pain (0.08), and less than: hip pain (0.12), stomach or abdominal pain (0.14), headache (0.21), facial pain (0.24), and pain all over the body (0.31) (51). Further, the genetic correlation matrix among 8 pain phenotypes in the

349 UK Biobank showed that the neck or shoulder pain and back pain shared the highest
350 genetic correlation (rg = 0.83) (51).

351 The genetic correlation analysis results were perhaps to be expected. Like knee pain 352 and back pain, which have been shown to be positively correlated with depression and neuroticism (51), neck or shoulder pain was correlated genetically and positively 353 with some mental health and personality phenotypes. We also identified that neck or 354 355 shoulder pain was genetically and negatively correlated with the age at which they have their first child, college completion, and years of schooling. This means that 356 357 those who were older when they had their first child, those with more years of 358 schooling, and those with completed college education were less likely to report neck or shoulder pain. These factors could be related to a number of factors including 359 360 lifestyle, deprivation levels, and occupation. It is interesting to note that males are more likely to report neck or shoulder pain than females in the UK Biobank 361 population. This is matched with the fact that males are more likely to have 362 363 strenuous occupations. However, we should note, in general, female sex is a risk factor for neck or shoulder pain. 364

The primary limitation of this study is that different (albeit similar) case and control 365 definitions were used in the discovery and replication cohorts. This was a 366 consequence of the pre-determined phenotypic information that was present in the 367 relevant cohorts. We defined neck or shoulder pain cases and controls based on the 368 responses by UK Biobank participants to a specific pain question. This question 369 focused on neck or shoulder pain occurrence during the previous month that was 370 371 sufficient to cause interference with activity. The severity, frequency, and exact location of the neck or shoulder pain were not documented. Hence, our phenotyping 372 should be considered as broadly defined. In the GS:SFHS and Twins UK cohorts, 373

374 the disease status of participants was also self-reported, while cases were those who having neck or shoulder pain over the past 3 months, controls were those who 375 376 could have neck or shoulder pain less than 3 months or have pain in other body sites. 377 While in the UK Biobank, controls were defined as pain free for the past month. Differences between (albeit similar) the case and control definitions could have a 378 negative impact on replication of the results while this impact is hard to evaluate 379 380 Differences between the case and control definitions could have a negative impact on replication of the results although this impact would be hard to evaluate. There 381 382 could also be some cases who report neck or shoulder pain as a result of underlying causes such as cancer and osteoarthritis in the neck and shoulder areas. Their 383 impact to the results would be very limited due to the small numbers. 384

In summary, we have identified 3 loci of genome-wide significance ($P < 5 \times 10^{-8}$) associated with neck or shoulder pain in the UK Biobank dataset using a GWAS approach. Two of these loci were replicated weakly in the GS:SFHS cohort. Identification of these loci now provides a foundation for future work into understanding genetic roles and aetiology in neck or shoulder pain.

390

391 ACKNOWLEDGEMENTS

We would like to thank all participants of the UK Biobank, Generation Scotland and TwinsUK cohorts who have provided necessary genetic and phenotypic information.

394 This research has been conducted using the UK Biobank Resource under 395 Application Number 4844.

396 Generation Scotland is grateful to all the families who took part, the general 397 practitioners and the Scottish School of Primary Care for their help in recruiting them, 398 and the whole Generation Scotland team, which includes interviewers, computer and

- 399 laboratory technicians, clerical workers, research scientists, volunteers, managers,
- 400 receptionists, healthcare assistants, and nurses.
- 401

402 Data availability

- 403 The GWAS summary statistics of neck or shoulder pain can be accessed through
- 404 https://figshare.com/articles/fourpainphenotype2/7699583
- 405

406 **Conflict of interest**

407 The authors declare that they have no conflict of interest.

408

409 AUTHOR CONTRIBUTIONS

- 410 WM organised the project, drafted the paper and contributed to the analysis. BWC
- and CH contributed to drafting the paper. MBF provided the TwinsUK replication. MA
- 412 performed the main UK Biobank GWAS analysis. AC and CH contributed to
- 413 GS:SFHS cohorts. HLH, HZ, XZ, CNAP, LC, TGH and FMKW provided essential
- 414 comments. AM and BS organised the project and provided comments.

415 **REFERENCES**

- 416 1. Vogt, M. T., Simonsick, E. M., Harris, T. B., et al. Neck and shoulder pain in 70-
- 417 to 79-year-old men and women: findings from the Health, Aging and Body 418 Composition Study. *Spine J.*, **3**, 435–441.
- Picavet, H. S. J. and Schouten, J. S. A. G. (2003) Musculoskeletal pain in the
 Netherlands: prevalences, consequences and risk groups, the DMC(3)-study. *Pain*, **102**, 167–178.
- 3. Slater, M., Perruccio, A. V and Badley, E. M. (2011) Musculoskeletal
 comorbidities in cardiovascular disease, diabetes and respiratory disease: the
 impact on activity limitations; a representative population-based study. *BMC Public Health*, **11**, 77.
- 426 4. Molsted, S., Tribler, J. and Snorgaard, O. (2012) Musculoskeletal pain in 427 patients with type 2 diabetes. *Diabetes Res. Clin. Pract.*, **96**, 135–140.
- Fernández-de-Las-Peñas, C., Galán-Del-Río, F., Alonso-Blanco, C., et al.
 (2010) Referred pain from muscle trigger points in the masticatory and neckshoulder musculature in women with temporomandibular disoders. *J. Pain*, **11**,
 1295–1304.
- 432 6. Rossi, M., Pasanen, K., Kokko, S., et al. (2016) Low back and neck and
 433 shoulder pain in members and non-members of adolescents' sports clubs: the
 434 Finnish Health Promoting Sports Club (FHPSC) study. *BMC Musculoskelet.*435 *Disord.*, **17**, 263.
- Wright, A. R., Shi, X. A., Busby-Whitehead, J., et al. (2009) The Prevalence of
 Neck and Shoulder Symptoms and Associations with Comorbidities and
 Disability: The Johnston County Osteoarthritis Project. *Myopain*, 23, 34–44.
- 439 8. Hoy, D., March, L., Woolf, A., et al. (2014) The global burden of neck pain:

estimates from the global burden of disease 2010 study. *Ann. Rheum. Dis.*, **73**,
1309–1315.

- March, L., Smith, E. U. R., Hoy, D. G., et al. (2014) Burden of disability due to
 musculoskeletal (MSK) disorders. *Best Pract. Res. Clin. Rheumatol.*, 28, 353–
 366.
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017)
 Global, regional, and national incidence, prevalence, and years lived with
 disability for 328 diseases and injuries for 195 countries, 1990-2016: a
 systematic analysis for the Global Burden of Disease Study 2016. *Lancet*(London, England), **390**, 1211–1259.
- Nilsen, T. I. L., Holtermann, A. and Mork, P. J. (2011) Physical exercise, body
 mass index, and risk of chronic pain in the low back and neck/shoulders:
 longitudinal data from the Nord-Trondelag Health Study. *Am. J. Epidemiol.*, **174**, 267–273.
- Webb, R., Brammah, T., Lunt, M., et al. (2003) Prevalence and predictors of
 intense, chronic, and disabling neck and back pain in the UK general
 population. *Spine (Phila. Pa. 1976).*, **28**, 1195–1202.
- Miranda, H., Viikari-Juntura, E., Martikainen, R., et al. (2001) A prospective
 study of work related factors and physical exercise as predictors of shoulder
 pain. *Occup. Environ. Med.*, **58**, 528–534.
- MacGregor, A. J., Andrew, T., Sambrook, P. N., et al. (2004) Structural,
 psychological, and genetic influences on low back and neck pain: a study of
 adult female twins. *Arthritis Rheum.*, **51**, 160–167.
- 463 15. Ostergren, P.-O., Hanson, B. S., Balogh, I., et al. (2005) Incidence of shoulder
 464 and neck pain in a working population: effect modification between mechanical

- and psychosocial exposures at work? Results from a one year follow up of the
 Malmö shoulder and neck study cohort. *J. Epidemiol. Community Health*, **59**,
 721–728.
- Feleus, A., Bierma-Zeinstra, S. M. A., Miedema, H. S., et al. (2007) Prognostic
 indicators for non-recovery of non-traumatic complaints at arm, neck and
 shoulder in general practice--6 months follow-up. *Rheumatology (Oxford).*, 46,
 169–176.
- 472 17. Bot, S. D. M., van der Waal, J. M., Terwee, C. B., et al. (2005) Incidence and
 473 prevalence of complaints of the neck and upper extremity in general practice.
 474 *Ann. Rheum. Dis.*, **64**, 118–123.
- Enthoven, P., Skargren, E. and Oberg, B. (2004) Clinical course in patients
 seeking primary care for back or neck pain: a prospective 5-year follow-up of
 outcome and health care consumption with subgroup analysis. *Spine (Phila. Pa.* 1976)., **29**, 2458–2465.
- Hoving, J. L., de Vet, H. C. W., Twisk, J. W. R., et al. (2004) Prognostic factors
 for neck pain in general practice. *Pain*, **110**, 639–645.
- Vos, C. J., Verhagen, A. P., Passchier, J., et al. (2008) Clinical course and
 prognostic factors in acute neck pain: an inception cohort study in general
 practice. *Pain Med.*, **9**, 572–580.
- Fejer, R., Hartvigsen, J. and Kyvik, K. O. (2006) Heritability of neck pain: a
 population-based study of 33,794 Danish twins. *Rheumatology (Oxford).*, 45,
 589–594.
- 487 22. Hartvigsen, J., Petersen, H. C., Pedersen, H. C., et al. (2005) Small effect of
 488 genetic factors on neck pain in old age: a study of 2,108 Danish twins 70 years
 489 of age and older. *Spine (Phila. Pa. 1976).*, **30**, 206–208.

- Ståhl, M. K., El-Metwally, A. A., Mikkelsson, M. K., et al. (2013) Genetic and
 environmental influences on non-specific neck pain in early adolescence: a
 classical twin study. *Eur. J. Pain*, **17**, 791–798.
- 493 24. Meng, W., Adams, M. J., Palmer, C. N. A., et al. (2019) Genome-wide 494 association study of knee pain identifies associations with GDF5 and 495 COL27A1 in UK Biobank. *Commun. Biol.*, **2**, 321.
- 496 25. Meng, W., Adams, M. J., Hebert, H. L., et al. (2018) A Genome-Wide
 497 Association Study Finds Genetic Associations with Broadly-Defined Headache
 498 in UK Biobank (N=223,773). *EBioMedicine*, **28**, 180–186.
- Suri, P., Palmer, M. R., Tsepilov, Y. A., et al. (2018) Genome-wide metaanalysis of 158,000 individuals of European ancestry identifies three loci
 associated with chronic back pain. *PLoS Genet.*, **14**, e1007601.
- 502 27. Bycroft, C., Freeman, C., Petkova, D., et al. (2018) The UK Biobank resource 503 with deep phenotyping and genomic data. *Nature*, **562**, 203–209.
- Smith, B. H., Campbell, H., Blackwood, D., et al. (2006) Generation Scotland:
 the Scottish Family Health Study; a new resource for researching genes and
 heritability. *BMC Med. Genet.*, **7**, 74.
- Smith, B. H., Campbell, A., Linksted, P., et al. (2013) Cohort profile: Generation
 scotland: Scottish family health study (GS: SFHS). The study, its participants
 and their potential for genetic research on health and illness. *Int. J. Epidemiol.*
- 30. Hall, L. S., Adams, M. J., Arnau-Soler, A., et al. (2018) Genome-wide metaanalyses of stratified depression in Generation Scotland and UK Biobank. *Transl. Psychiatry*, 8, 9.
- 31. Moayyeri, A., Hammond, C. J., Hart, D. J., et al. (2013) The UK Adult Twin
 Registry (TwinsUK Resource). *Twin Res. Hum. Genet.*, **16**, 144–149.

| 515 | 32. | Yang, J., Lee, S. H., Goddard, M. E., et al. (2011) GCTA: a tool for genome- |
|-----|-----|--|
| 516 | | wide complex trait analysis. Am. J. Hum. Genet., 88, 76–82. |


- 33. Watanabe, K., Taskesen, E., van Bochoven, A., et al. (2017) Functional
 mapping and annotation of genetic associations with FUMA. *Nat. Commun.*, 8,
 1826.
- 520 34. de Leeuw, C. A., Mooij, J. M., Heskes, T., et al. (2015) MAGMA: generalized 521 gene-set analysis of GWAS data. *PLoS Comput. Biol.*, **11**, e1004219.
- 522 35. Lai, C. S. L., Fisher, S. E., Hurst, J. A., et al. (2001) A forkhead-domain gene is 523 mutated in a severe speech and language disorder. *Nature*, **413**, 519–523.
- 524 36. Spiteri, E., Konopka, G., Coppola, G., et al. (2007) Identification of the 525 transcriptional targets of FOXP2, a gene linked to speech and language, in 526 developing human brain. *Am. J. Hum. Genet.*, **81**, 1144–1157.
- 527 37. Vernes, S. C., Spiteri, E., Nicod, J., et al. (2007) High-throughput analysis of 528 promoter occupancy reveals direct neural targets of FOXP2, a gene mutated in 529 speech and language disorders. *Am. J. Hum. Genet.*, **81**, 1232–1250.
- 38. Vargha-Khadem, F., Watkins, K., Alcock, K., et al. (1995) Praxic and nonverbal
 cognitive deficits in a large family with a genetically transmitted speech and
 language disorder. *Proc. Natl. Acad. Sci. U. S. A.*, **92**, 930–933.
- 533 39. Konopka, G., Bomar, J. M., Winden, K., et al. (2009) Human-specific
 transcriptional regulation of CNS development genes by FOXP2. *Nature*, 462,
 213–217.
- 40. Acampora, D., Merlo, G. R., Paleari, L., et al. (1999) Craniofacial, vestibular
 and bone defects in mice lacking the Distal-less-related gene Dlx5. *Development*, **126**, 3795–3809.
- 539 41. Yoshihara, M., Adolfsen, B., Galle, K. T., et al. (2005) Retrograde signaling by

- 540 Syt 4 induces presynaptic release and synapse-specific growth. *Science*, **310**,
 541 858–863.
- 542 42. Belton, E., Salmond, C. H., Watkins, K. E., et al. (2003) Bilateral brain
 543 abnormalities associated with dominantly inherited verbal and orofacial
 544 dyspraxia. *Hum. Brain Mapp.*, **18**, 194–200.
- 545 43. Yen, C.-T. and Lu, P.-L. (2013) Thalamus and pain. *Acta Anaesthesiol. Taiwan*,
 546 **51**, 73–80.
- 547 44. Brightwell, J. J. and Taylor, B. K. (2009) Noradrenergic neurons in the locus 548 coeruleus contribute to neuropathic pain. *Neuroscience*, **160**, 174–185.
- 549 45. Benarroch, E. E. (2006) Pain-autonomic interactions. *Neurol. Sci.*, **27 Suppl 2**,
 550 S130-5133.
- 551 46. Chudler, E. H. and Dong, W. K. (1995) The role of the basal ganglia in 552 nociception and pain. *Pain*, **60**, 3–38.
- Johnston, K. J. A., Adams, M. J., Nicholl, B. I., et al. (2019) Genome-wide
 association study of multisite chronic pain in UK Biobank. *PLoS Genet.*, **15**,
 e1008164.
- 556 48. Zhao, J., Xu, J., Wang, W., et al. (2018) Long non-coding RNA LINC-01572:28
 557 inhibits granulosa cell growth via a decrease in p27 (Kip1) degradation in
 558 patients with polycystic ovary syndrome. *EBioMedicine*, **36**, 526–538.
- 559 49. Okamoto, N., Fujikawa-Adachi, K., Nishimori, I., et al. (2001) cDNA sequence
 of human carbonic anhydrase-related protein, CA-RP X: mRNA expressions of
 561 CA-RP X and XI in human brain. *Biochim. Biophys. Acta*, **1518**, 311–316.
- 562 50. Visscher, P. M., Wray, N. R., Zhang, Q., et al. (2017) 10 Years of GWAS 563 Discovery: Biology, Function, and Translation. *Am. J. Hum. Genet.*, **101**, 5–22.
- 564 51. Meng, W., Adams, M. J., Reel, P., et al. (2019) Genetic correlations between

565 pain phenotypes and depression and neuroticism. *Eur. J. Hum. Genet.*

| 567 | LEGENDS |
|-----|---|
| 568 | Figure 1: The Manhattan plot of the GWAS on neck or shoulder pain using the UK |
| 569 | Biobank cohort (N=203,309). The dashed red line indicates the cut-off P value of 5 x |
| 570 | 10 ⁻⁸ . |
| 571 | |
| 572 | Figure 2: Tissue expression results on 30 specific tissue types by GTEx in the FUMA. |
| 573 | The dashed line shows the cut-off P value for significance with Bonferroni adjustment |
| 574 | for multiple hypothesis testing. |
| 575 | |
| 576 | Figure 3: Tissue expression results on 53 specific tissue types by GTEx in the FUMA. |
| 577 | The dashed line shows the cut-off P value for significance with Bonferroni adjustment |
| 578 | for multiple hypothesis testing. |
| 579 | |

-log10 P-value





preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 1

Chromosome

Figure 2





| | UK Biobank | | |
|----------------------------------|------------------------------|--------------------------------|------------------|
| Covariates | Cases | Controls | Р |
| Sex (male:female) Age (years) | 28093 : 25901 57.7 (7.82) | 71,480 : 77,832 56.9 (7.97) | <0.001 <0.001 |
| BMI (kg/m²) | 27.8 (4.85) | 26.7 (4.30) | <0.001 |

Table 1. Clinical characteristics of neck or shoulder pain cases and controls in the UK
 Biobank

BMI: body mass index

A chi-square test was used to test the difference of gender frequency between cases and controls and an independent t test was used for other covariates.

Continuous covariates were presented as mean (standard deviation).

Table 2. The summary statistics of the 4 significant and independent SNPs in the UK Biobank and the replication and meta-analysis results using the GS:SFHS and TwinsUK cohorts

| | | | UK Biobank Discovery stage | | | | GS:SFHS replication | | | TwinsUK replication | | | Meta- analysis | | |
|------------|-----|-----------|-------------------------------|--------------------------|---------|--------|---------------------|---------|--------|---------------------|---------|--------|--------------------------|---------|---|
| SNP | Chr | Position | MAF | Р | beta | se | Р | beta | se | Р | beta | se | Р | effects | P |
| rs2049604 | 7 | 113990352 | 0.3648 (T) | 3.26 x 10 ⁻⁸ | -0.0080 | 0.0015 | 0.0240 | -0.0088 | 0.0039 | 0.13 | -0.0188 | 0.0122 | 3.19 x 10 ⁻⁹ | | 0 |
| rs34291892 | 7 | 114058731 | 0.3772 (C) | 2.38 x 10 ⁻¹⁰ | -0.0092 | 0.0014 | 0.1068 | -0.0064 | 0.0039 | 0.11 | -0.0196 | 0.0124 | 7.07 x 10 ⁻¹² | | 0 |
| rs62053992 | 16 | 72389872 | 0.1819 (G) | 4.50 x 10 ⁻⁸ | -0.0098 | 0.0018 | 0.0202 | -0.0109 | 0.0047 | 0.94 | 0.0012 | 0.0158 | 4.36 x 10 ⁻⁹ | + | 0 |
| rs12453010 | 17 | 50316131 | 0.3926 (T) | 1.66 x 10 ⁻¹¹ | 0.0095 | 0.0014 | 0.1331 | 0.0058 | 0.0038 | 0.10 | 0.0199 | 0.0121 | 2.20 x 10 ⁻¹² | +++ | 0 |

rs34291892 was replaced by rs4727799 (r2=0.8736) as it does not exist in the GS:SFHS and TwinsUK cohorts.

UK Biobank N=203,309; GS:SFHS N= 19,632; TwinsUK N= 3,982

Chr: chromosome

MAF: minor allele frequency

Significant *P* values in the replication (P < 0.05) were in bold.

Table 3. The significant genetic correlation results by the LD hub between neck or shoulderpain with other phenotypes

| Trait 1 | Trait 2 | rg | Р |
|-----------------------|------------------------------|---------|--------------------------|
| Neck or shoulder pain | Depressive symptoms | 0.5522 | 3.41 x 10 ⁻³⁰ |
| Neck or shoulder pain | Insomnia | 0.5377 | 1.21 x 10 ⁻²¹ |
| Neck or shoulder pain | Neuroticism | 0.4417 | 2.00 x 10 ⁻²⁹ |
| Neck or shoulder pain | Major depressive disorder | 0.3968 | 5.75 x 10 ⁻⁰⁸ |
| Neck or shoulder pain | Ever vs never smoked | 0.3082 | 4.14 x 10 ⁻⁰⁸ |
| Neck or shoulder pain | Number of children ever born | 0.2616 | 2.03 x 10 ⁻⁰⁷ |
| Neck or shoulder pain | Coronary artery disease | 0.1965 | 1.66 x 10 ⁻⁰⁷ |
| Neck or shoulder pain | Waist-to-hip ratio | 0.1547 | 1.31 x 10 ⁻⁰⁵ |
| Neck or shoulder pain | Sleep duration | -0.2468 | 9.46 x 10 ⁻⁰⁷ |
| Neck or shoulder pain | Subjective well being | -0.2626 | 1.14 x 10 ⁻⁰⁶ |
| Neck or shoulder pain | Intelligence | -0.3229 | 2.23 x 10 ⁻¹⁷ |
| Neck or shoulder pain | Former vs Current smoker | -0.3600 | 5.87 x 10 ⁻⁰⁶ |
| Neck or shoulder pain | Years of schooling 2016 | -0.4373 | 5.18 x 10 ⁻⁵⁴ |
| Neck or shoulder pain | College completion | -0.4706 | 7.26 x 10 ⁻²⁶ |
| Neck or shoulder pain | Age of first birth | -0.4812 | 8.95 x 10 ⁻³⁷ |

rg: genetic correlation

The cut-off *P* value is 0.0002 (0.05/234).